C10orf126: A Potential Drug Target and Biomarker for Chromosome 10 Open Reading Frame 126

Target Name: C10orf126

NCBI ID: G283080

C10orf126

C10orf126: A Potential Drug Target and Biomarker for Chromosome 10 Open Reading Frame 126

Introduction

Chromosome 10 is one of the chromosomes responsible for generating the major histocompatibility complex (MHC), which plays a crucial role in immune response and regulation. Open reading frame (ORF) 126 is a non-coding RNA gene located on chromosome 10 that has been implicated in various cellular processes. C10orf126 has been identified as a potential drug target and biomarker due to its unique gene expression patterns and biological functions.

Understanding the C10orf126 gene

The C10orf126 gene is located at position 611.8 kb on chromosome 10q34. It encodes a non-coding RNA molecule that has been shown to have various functional roles in cellular processes, including regulating gene expression, DNA replication, and chromatin remodeling.

One of the most significant features of the C10orf126 gene is its ORF126 region, which is composed of 199nt of highly conserved RNA secondary structure. ORF126 has been shown to play a role in regulating gene expression by binding to various transcription factors, including histones ( H3K27me3) and RNA-binding protein (RBP). Experimental results show that the ORF126 region of the C10orf126 gene can bind to histones and RBP, thereby affecting gene expression levels.

C10orf126 as a drug target

C10orf126 has been identified as a potential drug target due to its unique expression patterns in various diseases. For example, high expression of C10orf126 has been shown to be associated with an increased risk of developing multiple sclerosis (MS), a progressive neurodegenerative disease. Additionally , decreased expression of C10orf126 has been linked to cancer, and thus, targeting C10orf126 may provide new insights into cancer development and treatment.

One of the most promising strategies for targeting C10orf126 is the use of small molecules. Small molecules can be designed to interact with C10orf126 and modulate its expression levels, potentially leading to therapeutic effects. Currently, several studies are investigating the potential therapeutic benefits of small molecules against C10orf126 in various diseases, including MS and cancer.

C10orf126 as a biomarker

In addition to its potential as a drug target, C10orf126 has also been identified as a potential biomarker for various diseases. For example, C10orf126 has been shown to be downregulated in various diseases, including MS, cancer, and neurodegenerative diseases. Thus, measuring the expression level of C10orf126 may provide a valuable diagnostic or therapeutic target in these diseases.

C10orf126 has also been shown to be involved in various signaling pathways, including immune response, cell cycle progression, and apoptosis. Thus, C10orf126 may serve as a potential biomarker for diseases associated with these signaling pathways, such as cancer and neurodegenerative diseases.

Conclusion

C10orf126 is a non-coding RNA molecule located on chromosome 10 that has been shown to play various roles in cellular processes. Its unique expression patterns and functions make it an attractive target for small molecules and biomarkers. Further research is needed to fully understand the role of C10orf126 in various diseases and to develop effective therapies targeting it.

Protein Name: Chromosome 10 Open Reading Frame 126

The "C10orf126 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C10orf126 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets